Business
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumorsInterim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to provide interim analysis data for approximately 50 patients with at least 18 weeks of follow-upCash, cash equivalents, and marketable securities of $165.8 million as of March 31, 2025, providing expected cash runway to end of 2026 PRINCETON, N.
About this update from Pmv Pharmaceuticals, Inc.
[{"type":"image","alt":"PMV Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"PMV Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/877923264781c86b6a593db1aa3fc22b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H9FAajfuuaIXn5mRAIFvSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/877923264781c86b6a593db1aa3fc22b","width":282,"height":81}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to provide interim analysis data for approximately 50 patients with at least 18 weeks of follow-up","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents, and marketable securities of $165.8 million as of March 31, 2025, providing expected cash runway to end of 2026","length":135,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":486,"olType":false},{"type":"text","content":"PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":361,"tagName":"p"},{"type":"text","content":"PMV Pharma plans to provide interim analysis data from the Phase 2 PYNNACLE trial in the middle of 2025. This interim analysis will include data for approximately 50 patients, of which approximately 40% are in the ovarian cancer cohort, who have been followed for at least 18 weeks.","length":282,"tagName":"p"},{"type":"text","content":"“Our registrational PYNNACLE trial continues to progress well and enrollment remains on track,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “I am very appreciative of the efforts of our team and their continued execution. We look forward to providing data from the inte...